期刊文献+

^18F-FDG PET/CT对可疑复发性宫颈癌的临床价值 被引量:13

Clinical impact of ^18F-FDG PET/CT on suspected cervical cancer recurrence
原文传递
导出
摘要 目的 探讨^18F-FDG PET/CT在可疑复发性宫颈癌临床诊疗中的价值.方法 回顾性分析51例宫颈癌根治后随访期间临床可疑复发的患者,记录患者的治疗资料、可疑复发表现、18F-FDG PET/CT显像结果、同期常规影像检查结果、病理及临床随访结果、PET/CT结果对临床诊疗的影响.结果 PET/CT诊断宫颈癌复发43例,最终经病理检查及临床随访证实复发性宫颈癌40例,盆腔脓肿2例,放射性肠炎1例;PET/CT未见恶性征象8例,病理检查及临床随访均未见异常.PET/CT诊断复发性宫颈癌灵敏度为100.00%(40/40),特异性为72.73%(8/11),准确性为94.12%(48/51).PET/CT指导制订临床诊疗及随访计划34例,改变治疗计划7例.与其他影像检查相比,PET/CT可发现更多的病灶.结论^18F-FDG PET/CT能有效诊断复发性宫颈癌,指导临床诊疗. Objective To evaluate the clinical impact of ^18F-FDG PET/CT on patients with suspected cervical cancer recurrence. Methods Fifty-one cervical cancer patients, clinically suspected to have tumor recurrence during follow-up, underwent^ 18F-FDG PET/CT examination. 1^8 F-FDG PET/CT results were compared with those of conventional images, as referred to histopathology or clinical follow-up. Impacts of 18F-FDG PET/CT were evaluated based on documented changes of clinical management. Results In total, 43 patients were found to have positive lesions by 18F-FDG PET/CT, in which 40 were true recurrence,but 2 were pelvic abscess and 1 was radiation enterocolitis. Other 8 patients were found negative by 18F-FDG PET/CT and confirmed by pathology or follow-up. In patient-based analyses, the sensitivity, specificity, and accuracy of 18F-FDG PET/CT for the detection of tumor recurrence were 100% (40/40), 72. 73% (8/11),and 94.12% (48/51) respectively. In 7 patients, the clinical management was changed due to 18F-FDG PET/CT findings. Conclusion 18F-FDG PET/CT is an efficient tool for determining the recurrence of cervical cancer and instructing the clinical management.
出处 《中华核医学杂志》 CAS CSCD 北大核心 2011年第2期73-76,共4页 Chinese Journal of Nuclear Medicine
关键词 宫颈肿瘤 肿瘤复发 局部 体层摄影术 发射型计算机 体层摄影术 X线计算机 脱氧葡萄糖 Cervix neoplasms Neoplasm recurrence, local Tomography, emission-computed Tomography, X-ray computed Deoxyglucose
  • 相关文献

参考文献3

二级参考文献23

  • 1熊樱,梁立治,郑敏,魏梅,沈扬.鳞状细胞癌抗原与子宫颈鳞状细胞癌的临床病理特征及预后的关系[J].中华妇产科杂志,2007,42(1):29-33. 被引量:36
  • 2Ferrandina G, Macchia G, Legge F, et al. Squamous cell carcinoma antigen in patients with locally advanced cervical carcinoma undergoing preoperative radiochemotherapy : association with pathological response to treatment and clinical outcome [J]. Oncology, 2008,74(1-2) :42-49.
  • 3Ohno T, Nakayama Y, Nakamota S, et al. Measurement of serum squamous cell carcinoma antigen levels as a predictor of radiation response in patients with carcinoma of the uterine cervix [ J ]. Cancer, 2003,97 : 3114-3120.
  • 4Forni F, Ferrandina G, Deodato F, et al. Squamous cell carcinoma in follow-up cervical cancer treated with radiotherapy : evaluation of cost-effectiveness [J]. Int J Radiat Oncal Biol Phys, 2007,69(4) : 1145-1149.
  • 5Hirakawa M, Nagai Y, Inamine M, et al. Predictive factor of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy [J]. Gynecol Oncol, 2005,108( 1 ) : 126-129.
  • 6Micke O, Prott FJ, Schafer U, et al. The impact of squamous cell carcinoma(SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer [J]. Anticancer Res, 2000,20 (6D):5113-5115.
  • 7Hong JH, Tsai CS, Chang TC, et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy [J]. Int J Radiat Oncol Biol Phys, 2004,60( 1 ) : 249-257.
  • 8Kidd EA, Siegel BA, Dehdashti F, et al. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival [J]. Cancer, 2007,110(8) : 1738-1744.
  • 9Kato H, Takita J, Miyazaki T, et al. Correlation of 18-F- fluorodeoxyglucose(FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma [J]. Anticancer Res, 2003,23(4) :3263-3272.
  • 10Chang TC, Law KS, Hong JH, et al. Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase Ⅱ study [J]. Cancer, 2004, 101(1):164-171.

共引文献20

同被引文献80

  • 1吴湖炳,王全师,王明芳,王欣璐,郭晓君.呋塞米介入试验在泌尿生殖系统肿瘤^(18)F-FDG PET/CT显像中的应用[J].中华核医学杂志,2005,25(4):206-208. 被引量:23
  • 2张晓洁.鳞状细胞癌抗原与糖类抗原CA125检测在宫颈癌诊断中的应用[J].中国全科医学,2007,10(21):1813-1814. 被引量:8
  • 3Lu YY, Chen JH, Liang JA, et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analy- sis[J]. Eur J Radiol, 2012, 81: 2411-2416.
  • 4Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder [ J ]. Eur Urol, 2008, 54: 303-314.
  • 5Patil VV, Wang ZJ, Sollitto RA, et al. ^18F-FDG PET/CT of tran- sitional cell carcinoma [ J ]. AJR Am J Roentgenol, 2009, 193 : W497 -504.
  • 6Powles T, Murray I, Brock C, et al. Molecular positron emission tomography and PET/CT imaging in urological malignancies [ J ]. Eur Urol, 2007, 51: 1511-1520.
  • 7Lin WY, Wang KB, Tsai SC, et al. Unexpected accumulation of ^18F-FDG in the urinary bladder after bladder irrigation and retrograde filling with sterile saline: a possible pitfall in PET examination[ J]. Clin Nuel Med, 2009, 34: 560-563.
  • 8Shen YY, Kao CH, Yeh LH, et al. Feasible method to successfully uncover a urothelial carcinoma in the urinary bladder on the FDG PET/CT scan masked by physiological urine radioactivity [ J ]. CAin Nucl Med, 2010, 35: 464-466.
  • 9Vicente AM, Castrejon AS, Munoz AP, et al. Impact of ^18F-FDG PET/CT with retrograde filling of the urinary bladder in patients with suspected pelvic malignancies [ J ]. J Nucl Med Technol, 2010, 38: 128-137.
  • 10Anjos DA, Etchebehere EC, Ramos CD, et al. ^18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer [J]. J Nucl Med, 2007, 48: 764-770.

引证文献13

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部